Mounjaro works by mimicking two hormones that are secreted by the small intestine after you eat: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), explains Zentner. The FDA is also evaluating the drug as a treatment for obesity a decision is expected this year. Mounjaro is a once-weekly injectable medication approved by the Food and Drug Administration in May 2022 for managing blood sugar in people with type 2 diabetes. Though there are some important differences in how it works. The most recent arrival is Mounjaro, or tirzepatide, which takes the benefits of Ozempic/Wegovy up another notch. Although the first such drug was approved for type 2 diabetes in 2010, these medicines have become well-known in the last decade-particularly semaglutide, which is marketed in the United States as Ozempic (for type 2 diabetes) and Wegovy (for weight loss). “It’s a biological and evolutionary safeguard to prevent us from dying,” she said.įor years, scientists have worked to find medications to treat this inappropriate starvation response, but most drugs have fallen short-until recently.Ī new class of drugs called GLP-1 agonists, originally developed to control blood sugar in patients with type 2 diabetes, have been found highly effective for weight loss as well. That’s why some people with obesity can literally stop eating yet not lose weight right away, or lose the weight more slowly than someone without obesity.
0 Comments
Leave a Reply. |